Mizuho has increased its price target for Corvus Pharmaceuticals to $20 following positive trial results. The stock is expected to perform well in January, making it a top pick for investors.

Read more at Investing.com: Mizuho raises Corvus Pharmaceuticals stock price target to $20 on strong trial data, Top January Pick